Gary Gemignani

Gentium SRL manufactures and develops biopharmaceutical products. It offers discovery, research, development and manufacture of drugs for the treatment and prevention of a variety of vascular diseases and conditions related to cancer and cancer treatments. The company was founded by Laura Iris Ferro and is headquartered in Villa Guardia, Italy.

Biodel, Inc. is a pharmaceutical company, which develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. The company develops product candidates by applying formulation technologies to existing drugs in order to improve their therapeutic profiles. Biodel was founded by Solomon S. Steiner and Erik Steiner on December 3, 2003 and is headquartered in Danbury, CT.

IASO Pharma, Inc. operated as a development stage biopharmaceutical company which focused on acquiring, developing and commercializing drugs for the treatment and prevention of infectious diseases and other serious illnesses. The company was founded on October 5, 2006 and is headquartered in San Diego, CA.

Solta Medical, Inc. designs, develops, manufactures and markets energy-based medical device systems for aesthetic applications. Its brands include Clear + Brilliant pélo, Thermage, Liposonix, VASER, Fraxel, Clear + Brilliant, and Isolaz systems which are used to address various aesthetic issues. The company was founded by Edward W. Knowlton on January 11, 1996 and is headquartered in Pleasanton, CA.

Acacia Pharma Group Plc is a holding company, which engages in the development and commercialization of pharmaceutical product. It focuses on the new nausea and vomiting treatments for surgical and cancer patients. The company was founded by Julian Clive Gilbert, Robert William Gristwood, and Andrew Muncey in 2007 and is headquartered in Duxford, the United Kingdom.

Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.